We randomly assigned patients with supratentorial glioblastoma to receive intravenous bevacizumab ( @ mg per kilogram of body weight every @ weeks ) or placebo , plus radiotherapy ( @ Gy @ days a week ; maximum , @ Gy ) and oral temozolomide ( @ mg per square meter of body-surface area per day ) for @ weeks .